Status:
COMPLETED
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.
Eligibility Criteria
Inclusion
- metastatic renal cell carcinoma (kidney cancer) with clear cell component
- no prior systemic therapy (including no prior adjuvant or neoadjuvant)
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- Blood Pressure \< or = 140/90mmHg
Exclusion
- brain/CNS metastasis
- using more than 2 blood pressure medications
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2016
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT00835978
Start Date
August 1 2009
End Date
February 1 2016
Last Update
May 30 2017
Active Locations (65)
Enter a location and click search to find clinical trials sorted by distance.
1
East Bay Medical Oncology/Hematology Medical Associates Inc.
Antioch, California, United States, 94531
2
Comprehensive Blood and Cancer Center
Bakersfield, California, United States, 93309
3
Bay Area Cancer Research Group, LLC
Pleasant Hill, California, United States, 94523
4
Diablo Valley Oncology and Hematology Medical Group Inc
Pleasant Hill, California, United States, 94523